News

OCD brain treatment could help control type 2 diabetes

13-06-18-2
A type of therapy used to help people with obsessive-compulsive disorder (OCD) could also benefit those with type 2diabetes.Researchers from the Netherlands say deep brain stimulation, which is normally used to electrically stimulate the part of the brain that deals with motivation, reward and addiction, may also improve blood sugar levels. A study was carried out, after the initial findings were discovered by accident, when an obese man with type 2 diabetesunderwent the deep brain treatment to help him control .

Dexcom’s integrated CGM receives FDA nod

7-05-18
Dexcom got the nod from the FDA to market their Dexcom G6, an integrated continuous glucose monitoring system (iCGM), making it the first interoperable CGM to get the designation. “We are a company of firsts, almost everything that has been done in our industry has been done by us first,” Dexcom CEO Kevin Sayer told MobiHealthNews, citing that Dexcom was the first company to have a seven day sensor and to connect to a smartphone. .

Type 1 diabetes in later life doubles risk of other autoimmune conditions, study reports

23-04-18
People who are diagnosed with type 1 diabetes in later life are twice as likely to develop other autoimmune conditions, a new study has shown.Researchers have highlighted the importance of coordination between healthcare teams in considering additional screeningamong those with adult-onset type 1 diabetes. The latest research from the Washington University School of Medicine in St. Louis, MO, involved more than 1,110 adults with type 1 diabetes, all of whom developed type 1 diabetes at varying ages. Between 2011-2017 .

Type 2 diabetes diagnosis before 40 increases early death risk, study reveals

20-03-18
Being diagnosed with type 2 diabetes before the age of 40 increases the risk of early death, according to new research.A UK study has shown those who develop the condition are 2.5 times more likely to pass away at a younger age, compared with those who are diagnosed after the age of 60. Dr Bob Young, who was involved in the study, said: “These important results add to the weight of evidence that type 2 diabetes in people .

Increased coffee intake associated with higher metabolic syndrome risk in type 1 diabetes

Coffee shop blur background with bokeh image .

Adults with type 1 diabetes who drink a minimum of five cups of coffee per day could have an increased risk of metabolic syndrome compared with those who drink less, researchers suggest.

These findings from scientists at the University of Helsinki, Finland, are the latest in a multitude of studies which have reviewed the relationship between coffee, diabetes and metabolism in recent years.

Last year, drinking more coffee was shown to reduce the risk of death in an international study, including among people with diabetes. Also in 2017, regular coffee intake was reported to lower the risk of type 2 diabetes

While this new study indicates heightened coffee consumption among people with type 1 diabetes may confer negative health aspects, future studies will need to explore and validate this association.

The researchers evaluated data from 1,040 adults with type 1 diabetes who were divided into four groups based on their coffee consumption, and determined potential associations regarding metabolic syndrome

Moderate (3-5 cups per day) and high (5+) coffee consumption increased the odds of metabolic syndrome, which was categorised by possessing at least three cardiovascular riskfactors: obesity, high blood pressure, high blood sugar levels, high triglyceride levels and/or low HDL-cholesterol.

These findings remained regardless of age, sex, energy intake, alcohol intake, smoking or physical activity. Moreover, increasing coffee intake was also shown to impair insulin resistance among participants.

But researchers stressed this is an association at most, and not intended as a warning for people with type 1 diabetes to drastically reduce or cut out their coffee consumption. 

“Whether habitual coffee consumption will have any negative or beneficial effects on health outcomes, in this population of patients with type 1 diabetes, will be assessed in future studies,” said the researchers.

The findings appear online in the journal Nutrition, Metabolism and Cardiovascular Diseases.

Insulet’s OmniPod. Business Front.

34611603

Insulet’s OmniPod

Business Front: Insulet appears to be doing well on the business side these days. New patient starts were up 20% this past year, while new pediatric patients were up a full 30% over the previous year. So more patients are starting the OmniPod than ever before, it seems. Insulet CEO Pat Sullivan says the company now has a total 85,000 OmniPod users, as of the end of 2015. 

Insulet sold its Neighborhood Diabetes Business (the mail order medical supply company it acquired a few years ago) to Liberty Medical early this month, meaning those OmniPod customers who used Neighborhood Diabetes as a durable medical equipment provider will now be switched to Liberty.

 

Higher Concentrated-Insulin Pods: Insulet’s excited about its partnership with Eli Lilly for developing OmniPod devices that will have both the concentrated U-200 and U-500insulins inside. They’re queuing up a clinical study the U-500 version now, and already have a third of the required patients signed up. Insulet expects both of these new Pods to be available in the next 2 or 3 years, offering more choice for PWDs who may need more insulin.

Immune system could be used to regulate insulin in type 2 diabetes.

27-12-17
Immune system could be used to regulate insulin in type 2 diabetes.The immune system could help regulate insulin in type 2 diabetes, according to new research from Switzerland. Scientists from the University of Basel report that triggering immune cells located in the pancreas could help prevent insulin production from failing in people with type 2 diabetes.In a study of overweight people with type 2 diabetes, the researchers identified a feedback mechanism in the pancreas which had a positive influence on insulin secretion.The impact .

Dexcom CGM users to have clearer way of understanding trend arrows

29-11-17
A new method allows young people and adults with type 1 diabetes to better understand and make better use of trend arrow data from the Dexcom G5 mobile continuous glucose monitor (CGM) for adapting insulin doses.The Dexcom G5 CGM displays trend arrows indicating whether blood glucose levels are rising or falling, and how fast this is happening. Previously published methods on how best to use this data to adjust insulin doses were deemed imperfect and/or not user-friendly.Two recent studies, conducted by researchers from Harvard .

OmniPod DASH & Horizon

omnipod-dash-1-09-17
Insulet was showing off its DASH platform, which is basically a locked-down Android phone that will eventually replace the PDM (controller unit) for its tubeless insulin pump. “Locked down” means the phone will have no other regular cellular capabilities or other apps available, nor will it have an integrated fingerstick glucose meter like the current PDM. It also means that users will basically be carrying around two smartphones — a lot to schlep, possibly .

Insulin Pumps

omnipod-with-pdm-31-07
 What They Do: Insulin pumps are devices that deliver insulin without the need for manual injections. They can administer both basal insulin and bolus (mealtime) insulin once users program the needed insulin dosing. Some new Medtronic systems can automatically suspend insulin dosing when glucose levels are low. Many pumps also come with built in bolus-calculators, which can reduce the hassle of manual insulin dose calculations. All pumps require the user to wear something directly on .